Mizuho Markets Americas LLC Cuts Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Key Points

• Mizuho Markets Americas LLC reduced its holdings in ANI Pharmaceuticals by 1.6%, selling 3,145 shares, and now owns approximately 197,473 shares valued at $13,221,000.
• ANI Pharmaceuticals' stock has surged 18.1%, currently priced at $81.48, with a market cap of $1.76 billion and a price-to-earnings ratio of -64.16.
• The company reported strong quarterly earnings, with EPS of $1.80 beating analysts' expectations, and revenue of $211.37 million, up 53.2% compared to the same quarter last year.

Mizuho Markets Americas LLC reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 197,473 shares of the specialty pharmaceutical company's stock after selling 3,145 shares during the period. Mizuho Markets Americas LLC owned 0.91% of ANI Pharmaceuticals worth $13,221,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Millennium Management LLC grew its stake in shares of ANI Pharmaceuticals by 89.3% in the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after acquiring an additional 473,097 shares in the last quarter. Deep Track Capital LP grew its stake in shares of ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after acquiring an additional 144,214 shares in the last quarter. Global Alpha Capital Management Ltd. grew its stake in shares of ANI Pharmaceuticals by 17.8% in the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after acquiring an additional 111,040 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of ANI Pharmaceuticals by 17,558.4% in the first quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock valued at $6,360,000 after acquiring an additional 94,464 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of ANI Pharmaceuticals by 80.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 196,319 shares of the specialty pharmaceutical company's stock valued at $10,853,000 after acquiring an additional 87,698 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Up 4.2%

ANI Pharmaceuticals stock traded up $3.40 during mid-day trading on Monday, hitting $84.88. 1,671,238 shares of the stock were exchanged, compared to its average volume of 461,717. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $87.95. The firm's fifty day simple moving average is $65.65 and its two-hundred day simple moving average is $64.08. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -110.23 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. During the same quarter last year, the business earned $1.02 EPS. The company's revenue was up 53.2% compared to the same quarter last year. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ANIP shares. Piper Sandler restated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. HC Wainwright upped their price objective on shares of ANI Pharmaceuticals from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Friday. Guggenheim reaffirmed a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Finally, Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $84.75.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider directly owned 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares in the company, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,681 shares of company stock worth $345,222. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.